

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/009,809	04/26/2002	Ronit Eisenberg	30836	1519
75	90 06/01/2006		EXAMINER	
Martin MOYNIHAN			CROWDER, CHUN	
PRTSI, Inc. P.O. Box 16446			ART UNIT	PAPER NUMBER
Arlington, VA 22215			1644	
			DATE MAILED: 06/01/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/009,809	EISENBERG ET AL.			
Office Action Summary	Examiner	Art Unit			
	Chun Crowder	1644			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status					
1) Responsive to communication(s) filed on <u>01</u>	<u>May 2006</u> .				
2a) This action is FINAL . 2b) ⊠ Th	is action is non-final.				
· · · · · · · · · · · · · · · · · · ·	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4)⊠ Claim(s) <u>44,46,52-56,59,60,63-70 and 72-80</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6) Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) <u>44, 46, 52-56, 59-60, 63-70, and 72</u>	<u>2-80</u> are subject to restriction and/o	r election requirement.			
Application Papers					
9) The specification is objected to by the Examin	ner.				
10)☐ The drawing(s) filed on is/are: a)☐ ad	•				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 					
 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). 					
* See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s)					
1) Notice of References Cited (PTO-892)	4) Interview Summary				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	-\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	Paper No(s)/Mail Date 5) Notice of Informal Patent Application (PTO-152)			
 Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0 Paper No(s)/Mail Date 	8) S) Notice of Informal P	atom ripphoduloff (1 10 102)			
S. Palent and Trademark Office					

Application/Control Number: 10/009,809 Page 2

Art Unit: 1644

DETAILED ACTION

1. The examiner of this application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Chun Crowder, Group Art Unit 1644, Technology Center 1600.

- 2. The instant application appears to be in sequence compliance for patent applications containing nucleotide sequence and/or amino acid sequence disclosures
- 3. Applicant's amendment, filed 05/01/2006, is acknowledged.

Claims 1-43, 45, 47-51, 57-58, 61-62, and 71 have been canceled.

Claims 44, 52, 63-66, and 74 have been amended.

Claims 75-80 have been added.

Claims 44, 46, 52-56, 59-60, 63-70, and 72-80 are pending.

Species Election

4. This application contains claims directed to the following patentably distinct species of the claimed inventions:

Applicant is required to elect <u>one specific method</u> of preventing mast cell degranulation comprising administering <u>one specific first agent</u>

- A) without secondary complex, OR
- B) with <u>one specific</u> secondary complex.

Application/Control Number: 10/009,809

Art Unit: 1644

These species are distinct because different agents differ in their structures, physicochemical properties and mode of action, and they do not share a common structure that is disclosed to be essential for common utility. Furthermore, the examination of these species would require different searches in the scientific literature. As such, it would be burdensome to search these Species together.

Applicant is required under 35 USC 121 to elect a single disclosed species to which the claims would be restricted if no generic claim is finally held to be allowable.

If either (A) or (B) is elected, applicant is further required to elect <u>one specific</u> first agent with <u>one specific</u> first segment (e.g. SEQ ID NO:3 as recited in claim 1) linked to <u>one specific second</u> segment (e.g. SEQ ID NO:2 as recited in claim 1).

If applicant elect (B), applicant is further required to elect <u>one specific second</u> complex molecule with <u>one specific</u> amino acid sequence.

These species are distinct because different agents differ in their structures, physicochemical properties and mode of action, and they do not share a common structure that is disclosed to be essential for common utility. Furthermore, the examination of these species would require different searches in the scientific literature. As such, it would be burdensome to search these Species together.

Applicant is required under 35 USC 121 to elect a single disclosed species to which the claims would be restricted if no generic claim is finally held to be allowable.

In addition, if either (A) or (B) is elected, applicant is required to elect **one** specific condition (e.g. nasal allergy as recited in claim 52).

Page 4

Application/Control Number: 10/009,809

Art Unit: 1644

These species are distinct because the pathological conditions differ in etiologies and therapeutic endpoints; thus each condition represents patentably distinct subject matter. Furthermore, the examination of species would require different searches in the scientific literature. As such, it would be burdensome to search these Species together.

Applicant is required under 35 USC 121 to elect a single disclosed species to which the claims would be restricted if no generic claim is finally held to be allowable.

5. Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. M.P.E.P. § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. § 103 of the other invention.

Application/Control Number: 10/009,809

Art Unit: 1644

6. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

- 7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).
- 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chun Crowder whose telephone number is (571) 272-8142. The examiner can normally be reached Monday through Friday from 8:30 am to 5:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Chun Crowder, Ph.D. Patent Examiner May 25, 2006 PHILLIP GAMBEL, PH.D 30
PRIMARY EXAMINER

TC 1600